Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)
Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on Sarepta Therapeutics today and set a price target of $19.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Ahmad is a 3-star analyst with an average return of 0.9% and a 54.73% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Regeneron, and Ocular Therapeutix.
The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.47 average price target.
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $399.36 million and a GAAP net loss of $179.95 million. In comparison, last year the company earned a revenue of $467.17 million and had a net profit of $33.61 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.
Read More on SRPT:
